

Exhibit 2 - Clinical Trials Potentially Impacted by COVID-19 continued

Company	Drug	Indication	Clinical trial	Anticipated timings (pre COVID-19)	Status/guidance	Modality	COVID-19 risk factors
Erytech	Eryaspase	Pancreatic cancer (second-line)	Phase III (TRYbeCA-1)	Interim data 3Q20E; headline data 1H21E	2/3 enrolled by end Feb; full enrolment expected 3Q20E for data 1H21E	IV	ORR & PFS secondary endpoints likely to require a scan or biopsy
		Pancreatic cancer (first-line, investigator sponsored)	Phase I	Expected to start 2H20E	US IND clearance has been received	IV	
		Triple negative breast cancer (first-line)	Phase II (TRYbeCA-2)	Data expected 2021E	Recruiting	IV	ORR & PFS endpoints likely to require a scan or biopsy
Galapagos	Filgotinib	Ulcerative colitis	Phase III (SELECTION)	Headline data 2Q20E	Fully enrolled, read-out unaffected	Oral (QD)	
		Crohn's disease	Phase III (DIVERSITY)	Headline data 2Q21E	Enrolment paused due to COVID-19	Oral (QD)	Co-primary endpoint requires endoscopy
		Psoriatic arthritis	Phase III (PENGUIN)	Headline data 1H22E	Enrolment paused due to COVID-19	Oral (QD)	
		Ankylosing spondylitis	Phase III	Expected to start 1Q20E (JEFe)	Initiation now expected 2H20E due to COVID-19	Oral (QD)	
		Testicular safety	Phase II (MANTA & MANTA-RAY)	Safety data 2Q20E (JEFe)	Enrolment paused due to COVID-19	Oral (QD)	
		Uveitis	Phase II (Humboldt)	Headline data 1H21E	Enrolment paused due to COVID-19	Oral (QD)	
	GLPG1690	Idiopathic pulmonary fibrosis	Phase III (ISABELA)	Interim futility analysis 1Q21E, headline data 1H22E	>50% patient enrolled sufficient for interim analysis; full enrolment was expected YE20	Oral (QD)	High risk patient population, endpoints require monthly follow ups
		Systemic sclerosis	Phase IIa (NOVESA)	Headline data 3Q20E	Fully enrolled Dec 2019	Oral (QD)	
	GLPG1972	Osteoarthritis	Phase IIa (ROCCELLA)	Headline data 4Q20E	Fully enrolled Jun 2019	Oral (QD)	Primary endpoint requires an MRI
	GLPG1205	Idiopathic pulmonary fibrosis	Phase IIa (PINTA)	Headline data 3Q20E	Fully enrolled early-2020	Oral (QD)	High risk patient population

Source: Company data; Jefferies research. Notes: QD, once a day; BID, twice a day; QW, once a week; LPLV, last patient last visit